In India, where healthcare challenges are as diverse as its population, brain tumors pose a significant threat with an estimated 40,000 new cases reported each year. This staggering statistic highlights the urgent need for early detection strategies in combating brain tumors, a perspective increasingly underscored within the pharmaceutical industry.
Whether a patient has a primary benign tumor or a subsequent malignant tumor, both can have catastrophic effects. The symptoms may be modest and irrelevant to be regarded, such as daily headaches or inexplicable vomiting. Seizures, memory loss, and poor coordination could follow. This makes early detection not only beneficial, but also essential. Patients' chances of survival and quality of life are significantly impacted by early brain tumor diagnosis.
